BREAKING: Block & Leviton Investigating Arvinas, Inc. (ARVN) For Securities Fraud After Shares Fall Over 20%; Investors Encouraged to Contact the Firm to Potentially Recover Losses

Core Viewpoint - Arvinas, Inc. shares dropped over 20% following the announcement of the discontinuation of vepdegestrant development, raising concerns about the company's transparency and management decisions [2]. Group 1: Company Developments - Arvinas, Inc. and Pfizer have decided to halt the development of vepdegestrant, an oral SERD for HR-positive breast cancer, which has led to the cancellation of two planned Phase 3 studies [2]. - The termination of the drug's development follows the earlier discontinuation of the VERITAC-3 study in January [2]. - Oppenheimer & Co. expressed surprise at the announcement and questioned the completeness of information provided by Arvinas' management [2]. Group 2: Investor Impact - Investors who have experienced losses in their Arvinas, Inc. investments are encouraged to contact Block & Leviton for potential recovery options [1][3]. - The investigation by Block & Leviton focuses on possible securities law violations by Arvinas, which may affect investor confidence and future stock performance [4]. Group 3: Legal and Recovery Options - Block & Leviton is a prominent securities class action firm that has successfully recovered billions for defrauded investors and is now investigating Arvinas [7]. - Investors with non-public information about Arvinas are encouraged to assist in the investigation or report to the SEC under the whistleblower program, which offers rewards for original information [6].